The results demonstrate that mice treated with the combination of Xcl1-E6E7 and IL-9 experienced earlier tumor regression and ultimately achieved a complete remission rate of 3 out of 5, compared to a 0 out of 5 remission rate for those treated with Xcl1-E6E7 alone (Figure 4J). This evidence concerns the gene IL9 and neoplasm.